Does intraperitoneal chemotherapy benefit optimally debulked epithelial ovarian cancer patients after neoadjuvant chemotherapy?

Abstract

Objective

To compare survival of ovarian cancer patients treated with neoadjuvant chemotherapy followed by intraperitoneal (IP) versus intravenous (IV) chemotherapy after optimal interval debulking.

Conclusions

Survival benefit associated with IP chemotherapy after optimal upfront surgery may not translate to the neoadjuvant setting.

Research Highlights

► Macroscopic residual disease is associated with worse prognosis.
► No difference observed in complete response between IP and IV treated patients.
► IP chemotherapy benefits may not translate to the neoadjuvant setting.